Can GLP‑1 receptor agonists cause palpitations?

GLP-1 Receptor Agonists and Palpitations

GLP-1 receptor agonists do cause a modest increase in heart rate (~5 beats per minute) but are not associated with clinically significant palpitations or arrhythmias, and their cardiovascular benefits far outweigh this minor chronotropic effect. 1

Understanding the Heart Rate Effect

GLP-1 receptor agonists consistently increase resting heart rate by approximately 5 beats per minute across multiple large cardiovascular outcomes trials 1. This effect is:

• Physiologically modest and occurs through direct sinoatrial node stimulation rather than sympathetic nervous system activation 2
• Not associated with increased blood pressure or other adverse cardiovascular events 1
• Not linked to increased arrhythmia risk in large meta-analyses of randomized controlled trials 3

Clinical Evidence on Arrhythmias

The most robust evidence shows no increased risk of cardiac arrhythmias with GLP-1 receptor agonists. A comprehensive 2022 meta-analysis of 56 randomized controlled trials involving 79,720 participants found that GLP-1 receptor agonists did not significantly increase the risk of:

• Atrial fibrillation (RR 0.97,95% CI 0.83-1.12)
• Atrial flutter (RR 0.83,95% CI 0.59-1.17)
• Ventricular arrhythmias (RR 1.24,95% CI 0.92-1.67)
• Sudden cardiac death (RR 0.89,95% CI 0.67-1.19) 3

Cardiovascular Safety Profile

GLP-1 receptor agonists demonstrate superior cardiovascular safety and benefit despite the minor heart rate increase. Major cardiovascular outcomes trials (LEADER, SUSTAIN-6) showed:

• 13% reduction in major adverse cardiovascular events with liraglutide 4
• 26% reduction in cardiovascular death, non-fatal MI, or stroke with semaglutide 4
• These benefits occurred despite the consistent 5 bpm heart rate increase 1

Practical Management Approach

When to Monitor More Closely

While palpitations are not a recognized adverse effect, monitor patients who report subjective symptoms:

• Document baseline heart rate before initiating therapy
• Reassess at follow-up if patient reports palpitations
• Consider beta-blockers only if symptomatic tachycardia develops (rare) 4

Common Pitfalls to Avoid

1. Do not confuse the modest heart rate increase with pathologic arrhythmia - the 5 bpm increase is physiologic and not associated with adverse outcomes 1

2. Do not withhold GLP-1 receptor agonists due to heart rate concerns - the cardiovascular benefits (mortality reduction, MACE reduction) far exceed any theoretical risk from mild chronotropic effects 1, 5

3. Do not attribute gastrointestinal symptoms to cardiac issues - nausea, vomiting, and diarrhea occur in 15-20% of patients and are the actual common side effects, not palpitations 6, 1, 6

What Patients Actually Experience

The most common adverse events are gastrointestinal, not cardiac 6:

• Nausea, vomiting, diarrhea (15-20% of patients)
• Injection site reactions (<1%)
• These typically resolve with dose titration over several weeks

Palpitations are not listed among the recognized adverse effects in major guidelines or cardiovascular outcomes trials 6, 1, 6, 7.

Bottom Line for Clinical Practice

If a patient on a GLP-1 receptor agonist reports palpitations, investigate other causes first (anxiety, caffeine, thyroid dysfunction, anemia, other medications). The drug class has an excellent cardiovascular safety profile with proven mortality benefits 1, 5. The modest heart rate increase is a known pharmacologic effect that does not translate to symptomatic palpitations or increased arrhythmia risk in clinical trials 3.